MVAL - ETF AI Analysis

Top Page

VanEck Morningstar Wide Moat Value ETF (MVAL)

Rating:70Neutral

Price Target:―

MVAL, the VanEck Morningstar Wide Moat Value ETF, earns a solid overall rating thanks to several high-quality holdings like Microsoft, Bristol-Myers Squibb, and GE Healthcare, which bring strong financial performance, growth prospects, and positive earnings outlooks to the portfolio. The fund is somewhat held back by weaker names such as Clorox, where financial instability and operational disruptions add risk, and by pockets of overvaluation or bearish trends in a few other holdings. The main risk factor is that several key positions face valuation and market challenges, which could increase volatility even though the overall mix of wide-moat companies supports long-term quality.

Positive Factors

Defensive Sector Tilt

A large share of the fund is in consumer defensive and health care companies, which can help provide stability during market downturns.

Select Strong Performers in Top Holdings

Some of the largest positions, such as Kenvue, Bristol-Myers Squibb, and Masco, have shown strong gains this year, supporting the ETF’s overall results.

Positive Recent Performance

The ETF has delivered positive returns so far this year and over the past month, indicating recent upward momentum.

Negative Factors

High U.S. Concentration

With almost all assets invested in U.S. companies, the fund offers little geographic diversification and is heavily tied to the U.S. economy.

Several Weak Top Holdings

A number of major positions, including Danaher, GE Healthcare, Nike, Clorox, and Constellation Brands, have shown weak performance this year, which can drag on the fund’s returns.

Moderate Expense Ratio

The fund’s expense ratio is not especially low, meaning investors pay a noticeable ongoing fee compared with some cheaper ETFs.

MVAL vs. SPDR S&P 500 ETF (SPY)

AUM1.88M

RegionNorth America

Expense Ratio0.50%

Beta0.74

IssuerVanEck

Inception DateMar 26, 2024

Dividend YieldN/A

Asset ClassEquity

Index TrackedMorningstar US Broad Value Wide Moat Focus Index - Benchmark TR Gross

Share Statistics

EPS (TTM)N/A

Shares OutstandingN/A

10 Day Avg. Volume246

30 Day Avg. Volume531

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

43.28

Price Target Upside― Downside

Rating ConsensusModerate Buy

Number of Analyst Covering45

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

MVAL Summary

MVAL is the VanEck Morningstar Wide Moat Value ETF, which follows the Morningstar US Broad Value Wide Moat Focus Index. It invests mainly in U.S. companies that Morningstar believes have strong, lasting competitive advantages and are trading at attractive prices. The fund holds well-known names like Bristol-Myers Squibb and Nike, and spreads your money across defensive sectors such as consumer goods and health care. Someone might invest in MVAL for long-term growth and diversification into high-quality value stocks. A key risk is that these stocks can still go up and down with the overall stock market.

How much will it cost me?The VanEck Morningstar Wide Moat Value ETF (MVAL) has an expense ratio of 0.49%, which means you’ll pay $4.90 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed, focusing on selecting companies with strong competitive advantages. Active management typically involves more research and analysis, which can lead to higher costs.

What would affect this ETF?The VanEck Morningstar Wide Moat Value ETF (MVAL) could benefit from long-term growth in sectors like Health Care and Consumer Defensive, which are its largest exposures and tend to perform well during economic uncertainty. However, rising interest rates or economic slowdowns could negatively impact industrial and cyclical sectors, which also make up a significant portion of the ETF's holdings. Regulatory changes or competitive pressures affecting top holdings like Thermo Fisher or Nike may also influence the ETF's performance.

MVAL Top 10 Holdings

MVAL is leaning heavily on U.S. health care and consumer defensive names, with Bristol-Myers Squibb, Danaher, and Zimmer Biomet acting as key engines of recent gains as their shares keep rising on solid fundamentals. On the consumer side, Brown-Forman and Clorox are steady contributors, while Kenvue looks more mixed, occasionally losing steam. Microsoft adds a dash of Big Tech strength, giving the fund a modern edge without dominating the lineup. Overall, performance is being driven by a handful of wide-moat health care leaders, with only a few holdings modestly dragging their feet.

Name	Company Name	Weight %	Market Value	Market Cap	Yearly Gain	Overall Rating
BMY	Bristol-Myers Squibb	4.84%	$96.55K	$136.49B	41.48%	78 Outperform
DHR	Danaher	4.50%	$89.69K	$145.98B	6.86%	75 Outperform
ZBH	Zimmer Biomet Holdings	4.46%	$88.93K	$18.71B	-5.56%	73 Outperform
BF.B	Brown-Forman B	4.35%	$86.71K	$12.33B	-3.12%	74 Outperform
KVUE	Kenvue, Inc.	4.32%	$86.26K	$36.00B	-2.54%	73 Outperform
CLX	Clorox	3.67%	$73.26K	$11.25B	-25.95%	55 Neutral
STZ	Constellation Brands	3.62%	$72.29K	$16.60B	-12.19%	67 Neutral
GEHC	GE Healthcare Technologies Inc	3.57%	$71.18K	$31.10B	-15.16%	78 Outperform
MSFT	Microsoft	3.27%	$65.30K	$3.71T	-0.89%	79 Outperform
SCHW	Charles Schwab	2.81%	$56.07K	$189.00B	16.95%	74 Outperform

MVAL Technical Analysis

Technical Analysis Sentiment

Negative

Last Price―

Price Trends

50DMA

38.36

Negative

100DMA

37.18

Positive

200DMA

37.11

Positive

Market Momentum

MACD

-0.14

Positive

RSI

32.93

Neutral

STOCH

<0.01

Positive

Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MVAL, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 39.19, equal to the 50-day MA of 38.36, and equal to the 200-day MA of 37.11, indicating a neutral trend. The MACD of -0.14 indicates Positive momentum. The RSI at 32.93 is Neutral, neither overbought nor oversold. The STOCH value of <0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MVAL.

MVAL Peer Comparison

Comparison Results

Name	Price	Price Target	AUM	Expense Ratio	Overall Rating
MVAL	―	―	$1.88M	0.50%	70 Neutral
VUSV	―	―	$93.80M	0.30%	67 Neutral
SASS	―	―	$77.51M	0.75%	69 Neutral
RAUS	―	―	$61.32M	―	74 Outperform
CVAR	―	―	$46.75M	0.87%	59 Neutral
GVLE	―	―	$46.08M	0.45%	70 Outperform

Performance Comparison

MVAL

VanEck Morningstar Wide Moat Value ETF

37.40

3.84

11.44%

VUSV

Vanguard Wellington U.S. Value Active ETF

―

SASS

M.D. Sass Concentrated Value ETF

―

RAUS

RACWI US ETF

―

CVAR

Cultivar ETF

―

GVLE

Goldman Sachs Value Opportunities ETF

―

Glossary

BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―

Table of Contents